Chronic lymphocytic leukemia
ICD-10 C91.1 · ICD-11 2A82.0

Treatment of Active CLL with Unmutated IGHV Status in Medically Fit Patients Without TP53 Mutation or del(17p)

This protocol addresses the management of active chronic lymphocytic leukemia (CLL) in a specific, well-defined patient population where molecular profiling shapes treatment selection.

Clinical scenario

The patient has active CLL with the following characteristics:

  • Unmutated IGHV status
  • No TP53 mutation detected
  • No del(17p) chromosomal abnormality
  • Medically fit (eligible for intensive therapy)

Unmutated IGHV status is a recognized prognostic marker in CLL. Current evidence supports a preference for time-limited therapy approaches in this population when efficacy is comparable.

Treatment approach (overview)

For eligible patients in this setting, the structured protocol includes consideration of transplantation-based strategies and, within the context of clinical trials, emerging cellular immunotherapy options.

The complete protocol specifies the criteria, sequencing, and conditions under which each approach applies — access it below.

Instant Access to Structured Evidence-Based Regimens

References

Condition:

  • CLL with unmutated IGHV status and without TP53 mutation or del(17p) (if there was similar efficacy, panel is giving preference to time-limited therapies).
  • Fit patients: ibrutinib [I, A] (data for other BTKis for fit patients are still pending); CIT should be avoided due to survival disadvantage, but may be used if other options are not available [I, A]. Venetoclax plus obinutuzumab might be an alternative to BTKis, but data for fit patients are still pending [III, A].

Treatment:

  • Allogeneic stem cell transplantation (alloSCT) should be considered in: Patients refractory to CIT and to novel inhibitor therapy, even for patients with a higher risk of non-relapse mortality [haematopoietic cell transplant comorbidity index (HCT-CI) score of 3] [III, B].
  • Treatment with chimeric antigen receptor T (CAR-T) cells or bi-specific T-cell engager (BiTE) antibodies within clinical trials could be an alternative to alloSCT for all three groups [V, B].
View source ↗